Health Monthly Martinique
SEE OTHER BRANDS

Exploring the health and wellness news of Martinique

Health Monthly Martinique: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monthly Martinique.

Press releases published on July 3, 2025

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)…

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO)…

Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by …

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July …

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired employees restricted stock units (RSUs) …

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED to Announce 2025 Half-Year Financial Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 03, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2025 on Thursday, August 7, 2025 at 7:00 …

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform OBT receives milestone payment associated with advance of drug candidate Oxford, …

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team

Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team Egham, UK – 03 July 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for …

Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises

Nixol Weight Loss Capsules UK & IE Officially Launched- Exploring the Science Behind its Weight Loss Tablets Promises

New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight …

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date …

Theratechnologies conclut un accord définitif en vue de son acquisition par CB Biotechnology, un membre du même groupe que Future Pak

Theratechnologies conclut un accord définitif en vue de son acquisition par CB Biotechnology, un membre du même groupe que Future Pak

Une offre de 3,01 $ US en espèces plus un droit conditionnel à la valeur représentant des paiements supplémentaires totaux potentiels pouvant atteindre 1,19 $ US par action La contrepartie initiale et la contrepartie totale en espèces potentielles …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service